251 related articles for article (PubMed ID: 34362557)
1. Convalescent Covid-19 plasma: Back-to-basics and ethics, and next steps.
Garraud O; Burnouf T
Transfus Clin Biol; 2021 Aug; 28(3):225-227. PubMed ID: 34362557
[No Abstract] [Full Text] [Related]
2. COVID-19 vaccination: The impact on the selection criteria of the convalescent plasma donors.
Bansal N; Raturi M; Bansal Y
Transfus Clin Biol; 2021 Aug; 28(3):308-309. PubMed ID: 33971319
[TBL] [Abstract][Full Text] [Related]
3. Convalescent Blood: Current Perspective on the Efficacy of a Legacy Approach in COVID-19 Treatment.
Sheervalilou R; Shirvaliloo M; Sargazi S; Bahari S; Saravani R; Shahraki J; Shirvalilou S; Shahraki O; Nazarlou Z; Shams Z; Ghaznavi H
Blood Purif; 2022; 51(1):1-14. PubMed ID: 33789273
[TBL] [Abstract][Full Text] [Related]
4. Locally harvested Covid-19 convalescent plasma could probably help combat the geographically determined SARS-CoV-2 viral variants.
Raturi M; Kusum A; Kala M; Mittal G; Sharma A; Bansal N
Transfus Clin Biol; 2021 Aug; 28(3):300-302. PubMed ID: 33971318
[TBL] [Abstract][Full Text] [Related]
5. Preparedness and activities of the anti-SARS-CoV-2 convalescent plasma bank in the Veneto region (Italy): An organizational model for future emergencies.
De Silvestro G; Gandini G; Fiorin F; Marson P; Barbone E; Frigato A; Gessoni G; Veronesi A; Pacenti M; Castelli M; Rinaldi M; Rizzi M; Stefani F; Roveroni G
Transfus Apher Sci; 2021 Aug; 60(4):103154. PubMed ID: 33994107
[TBL] [Abstract][Full Text] [Related]
6. Antibodies, epicenter of SARS-CoV-2 immunology.
Pecetta S; Pizza M; Sala C; Andreano E; Pileri P; Troisi M; Pantano E; Manganaro N; Rappuoli R
Cell Death Differ; 2021 Feb; 28(2):821-824. PubMed ID: 33500559
[No Abstract] [Full Text] [Related]
7. SARS-CoV-2 variants and convalescent plasma: reality, fallacies, and opportunities.
Casadevall A; Henderson JP; Joyner MJ; Pirofski LA
J Clin Invest; 2021 Apr; 131(7):. PubMed ID: 33621214
[No Abstract] [Full Text] [Related]
8. Thinking more about therapy with convalescent plasma for COVID-19 patients.
Han G; Zhou YH
Hum Vaccin Immunother; 2020 Nov; 16(11):2601-2603. PubMed ID: 32643512
[No Abstract] [Full Text] [Related]
9. How should we use convalescent plasma therapies for the management of COVID-19?
Wood EM; Estcourt LJ; McQuilten ZK
Blood; 2021 Mar; 137(12):1573-1581. PubMed ID: 33202419
[TBL] [Abstract][Full Text] [Related]
10. New generation of vaccines and convalescent plasma therapy for management of CoV-2: Perspectives from the UK and potential deployment in the current global pandemic.
Seghatchian J
Transfus Apher Sci; 2021 Feb; 60(1):103051. PubMed ID: 33461918
[No Abstract] [Full Text] [Related]
11. The convalescent sera option for containing COVID-19.
Casadevall A; Pirofski LA
J Clin Invest; 2020 Apr; 130(4):1545-1548. PubMed ID: 32167489
[No Abstract] [Full Text] [Related]
12. COVID-19 Pandemic and Virtual Clinics for Diabetes Care.
Garg SK; Reinicke T
Diabetes Technol Ther; 2021 Jun; 23(S2):S3-S15. PubMed ID: 34061640
[No Abstract] [Full Text] [Related]
13. Decrease in serum antibodies to SARS-CoV-2 in convalescent plasma donors over time.
Prus K; Alquist CR; Cancelas JA; Oh D
Transfusion; 2021 Feb; 61(2):651-654. PubMed ID: 33616966
[No Abstract] [Full Text] [Related]
14. Convalescent Plasma Therapy for COVID-19: Lessons from SARS-CoV, MERS-CoV, and H1N1 Infection.
Hosseini P; Rahimi H; Najafabadi MM; Ghorbani A; Najafabadi SK; Faridzadeh A; Arabpour J; Khormali E; Deravi N
Acta Med Indones; 2021 Jan; 53(1):86-95. PubMed ID: 33818411
[TBL] [Abstract][Full Text] [Related]
15. Plasma from donors convalescent from SARS-CoV-2 infection-A matter of priorities.
Farrugia A
Transfus Clin Biol; 2020 Aug; 27(3):167-168. PubMed ID: 32563550
[No Abstract] [Full Text] [Related]
16. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.
Wang P; Nair MS; Liu L; Iketani S; Luo Y; Guo Y; Wang M; Yu J; Zhang B; Kwong PD; Graham BS; Mascola JR; Chang JY; Yin MT; Sobieszczyk M; Kyratsous CA; Shapiro L; Sheng Z; Huang Y; Ho DD
Nature; 2021 May; 593(7857):130-135. PubMed ID: 33684923
[TBL] [Abstract][Full Text] [Related]
17. Challenges in the Production of Convalescent Hyperimmune Plasma in the Age of COVID-19.
Franchini M; Del Fante C; Klersy C; Glingani C; Percivalle E; Baldanti F; Perotti C
Semin Thromb Hemost; 2020 Oct; 46(7):804-806. PubMed ID: 32512588
[No Abstract] [Full Text] [Related]
18. Antibody response and therapy in COVID-19 patients: what can be learned for vaccine development?
Lu L; Zhang H; Zhan M; Jiang J; Yin H; Dauphars DJ; Li SY; Li Y; He YW
Sci China Life Sci; 2020 Dec; 63(12):1833-1849. PubMed ID: 33355886
[TBL] [Abstract][Full Text] [Related]
19. Position paper on the preparation of immune plasma to be used in the treatment of patients with COVID-19.
Accorsi P; Berti P; de Angelis V; De Silvestro G; Mascaretti L; Ostuni A;
Blood Transfus; 2020 May; 18(3):163-166. PubMed ID: 32453687
[TBL] [Abstract][Full Text] [Related]
20. Covid-19 convalescent plasma therapy: Analyzing the factors that led to its failure in India.
Bansal N; Raturi M; Bansal Y
Transfus Clin Biol; 2021 Aug; 28(3):296-298. PubMed ID: 34102319
[No Abstract] [Full Text] [Related]
[Next] [New Search]
